Sellas Life Sciences Shares Rise Following Anticipation of Pivotal Leukemia Trial Results
Sellas Life Sciences Group (SLS) saw its shares surge 20% in extended trading following the announcement that pivotal clinical trial results for its leukemia treatment are expected later this month. The stock jump comes as investors react to the upcoming data readout, which is viewed as a significant catalyst for the company's valuation. In addition to the trial update, the company reported quarterly earnings that showed a loss per share consistent with Wall Street analyst expectations. While the financial results met consensus, the market focus remains heavily weighted toward the clinical outcome of the upcoming leukemia study.
Tickers: $SLS
Topics: Clinical Trials Earnings Report Stock Price Movement
Read the full article at Seeking Alpha
Part of the story SELLAS Life Sciences Group, Inc. - 8-K Filing (5 articles)